Debiopharm’s investment portfolio company Novadiscovery offering the clinical trial simulation platform, Jinkō, to predict drug efficacy and optimize clinical trial development, has entered into a collaboration with Janssen France to provide in silico-based decision support for its clinical development pipeline.
François-Henri Boissel, CEO, Novadiscovery, commented
We are proud to have been selected by a leading pharmaceutical company to help provide answers to key clinical development questions in the future of healthcare. We are excited to join with Janssen France as it adopts this new technology, and we envisage a long and productive collaboration.
Access their full press release here and their corporate website here.